Please use this identifier to cite or link to this item:
|Title:||New anticonvulsants.||Austin Authors:||Vajda, F J||Affiliation:||Department of Neurology, Austin Hospital, University of Melbourne, Heidelberg, Victoria, Australia||Issue Date:||1-Aug-1992||Publication information:||Current Opinion in Neurology and Neurosurgery; 5(4): 519-25||Abstract:||The development of antiepileptic drugs has been rather slow, and this may be related partly to the regulatory requirement to show unequivocal benefit of a new agent over existing drugs. There is a need to reconsider trial protocols to achieve this objective. Five new drugs, vigabatrin (GVG), lamotrigine (LTG), gabapentin (GPT), felbamate and oxcarbazepine (OCBZ) appear to be the most widely tested and promising agents. Of the others, loreclezole and stiripentol (STP) are showing the highest potential for therapeutic application. Clobazam appears to be more effective than implied from earlier reports.||Gov't Doc #:||1325225||URI:||http://ahro.austin.org.au/austinjspui/handle/1/9555||URL:||https://pubmed.ncbi.nlm.nih.gov/1325225||Type:||Journal Article||Subjects:||Animals
Receptors, GABA-A.drug effects.physiology
Synaptic Transmission.drug effects.physiology
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.